Clinical Trial Update: Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of imatinib and rituximab for cutaneous sclerosis in chronic graft-versus-host disease has completed and results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Systemic Sclerosis

Drugs mentioned

• Imatinib (imatinib)
• Rituximab (rituximab)

Snippet

Sponsor: Lee, Stephanie | Conditions: Graft Versus Host Disease, Systemic Scleroderma | Phase 2 | Status: COMPLETED | Results posted: 2016-06-15